Maxim Group Downgrades Biotricity to Hold
Maxim Group analyst Allen Klee downgrades Biotricity (NASDAQ:BTCY) from Buy to Hold.
HC Wainwright & Co. Maintains Buy on Biotricity, Lowers Price Target to $2
HC Wainwright & Co. analyst Kevin Dede maintains Biotricity (NASDAQ:BTCY) with a Buy and lowers the price target from $6 to $2.
